Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma

Increasing cure rates of solid tumors by immune checkpoint inhibitors, Experimental Hematology & Oncology

Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy

Weighing the Pros and Cons of Neoadjuvant Anti–PD-1 Versus Neoadjuvant Combination Ipilimumab/Nivolumab in Melanoma

The Miller Lab - Neoadjuvant Nivo/Rela for Resectable Melanoma

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy - Smithers - 2021 - ANZ Journal of Surgery - Wiley Online Library

ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801

KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC

Study shows immunotherapy before and after surgery for advanced melanoma lowers recurrence - UT Health San Antonio